Skip to content
2000
Volume 16, Issue 19
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

By updating John Littleton's work published 15 years ago this review summarizes recent work on pharmacodynamic aspects of acamprosate and the perspective for future developments. In addition to insights into the role of glutamatergic receptor systems, craving and relapse inspired by acamprosate, clinical research points towards one question: if we knew how acamprosate works, we might also be able to generate hypotheses, for whom it does work. Recent research on acamprosate tightly links pre-clinical and clinical research that includes molecular biology, animal models, pharmacogenetic and imaging genetic trials, and clinical efficacy studies. To increase the efficacy of this drug, targeted treatment and individualized therapy approaches seem useful and necessary.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161210791516341
2010-06-01
2025-06-20
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161210791516341
Loading

  • Article Type:
    Research Article
Keyword(s): acamprosate; Alcoholism; craving; ethanol; glutamate; pharmacodynamics
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test